Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. As of February 7, 2025, Abliva AB (publ) operates as a subsidiary of Pharming Technologies B.V.
Frequently asked questions
What sector does Abliva AB (ABLI) operate in?
Abliva AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Abliva AB (ABLI) current stock price?
As of the latest data, Abliva AB stock price is SEK 0.44, with a previous close of SEK 0.44. Abliva AB gained SEK 0.00 in the last trading session, representing a 0.23% increase.
What is Abliva AB (ABLI) current market capitalization?
Abliva AB market cap is approximately 715.67 million.
What is Abliva AB (ABLI) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.07, and the forward EPS is -SEK 0.10.
Does Abliva AB (ABLI) pay dividends?
No. Abliva AB does not pay a dividend.
What is Abliva AB (ABLI) beta (volatility) score?
Abliva AB has a beta of 0.750, indicating lower volatility than the overall market.
